Fiche publication
Date publication
janvier 2004
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P
Lien Pubmed
Résumé
The survival benefit associated with first-line chemotherapy in advanced lung cancer led to the need for second-line chemotherapy. Docetaxel (Taxotere) has proven efficacy in both settings. This study evaluated the safety and efficacy of two doses of docetaxel in patients with non-small-cell lung cancer who had failed first-line platinum-based chemotherapy.
Mots clés
Adult, Aged, Antineoplastic Agents, Phytogenic, administration & dosage, Carcinoma, Non-Small-Cell Lung, drug therapy, Disease Progression, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Lung Neoplasms, drug therapy, Male, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, chemically induced, Safety, Survival Analysis, Taxoids, administration & dosage, Time Factors, Treatment Failure, Treatment Outcome
Référence
Ann. Oncol.. 2004 Jan;15(1):38-44
